#CMOncologyNews?is a biweekly newsletter that focuses on the latest developments in the field of oncology. The newsletter provides updates on clinical trials, new treatments, and emerging technologies in cancer care. It is designed for oncologists, researchers, and healthcare professionals who want to stay up-to-date with the latest trends and insights in oncology.
- Nexo Therapeutics have raised $60m in a Series A financing round. The funding supports Nexo’s platform, which uses covalent ligand discovery and chemical biology to develop new cancer therapies targeting previously difficult targets.
-
Kriya Therapeutics, Inc.
have added $150 million to their Series C funding round. The company now aims to move its undisclosed gene therapies into the clinic alongside the further scaling of its computational, engineering and manufacturing platforms.
-
SURGE Therapeutics
have raised a $32 million Series B financing round. The funding will be used to advance clinical development of the SURGE? intraoperative immunotherapy programs.
-
Gilead Sciences
' Trodelvy has picked up an approval for certain patients with pre-treated HR+/HER2- metastatic breast cancer. Specifically, the drug is approved as a monotherapy for patients with?unresectable or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy, plus at least two additional systemic therapies in the advanced setting.?
- The
FDA
has accepted an NDA for
Elevar Therapeutics
' combination therapy for?unresectable liver cancer. The combo (rivoceranib?plus?Jiangsu Hengrui Pharma’s PD-1 inhibitor?camrelizumab) was approved for first-line use in?China?in February and now is?set up for a potential market battle with?Roche’s PD-L1/VEGF combo of?Tecentriq?and?Avastin.
-
辉瑞
have switched up their R&D leadership for an "oncology-streamlined" approach.
Chris Boshoff, MD, PhD, FMedSci
will join the C-suite as Chief Oncology R&D Officer whilst current Chief Development Officer,
William Pao, MD, PhD
, will leave the company.
- Chief Medical Officer - Boston
- Principal Scientist (Med Chem) - Boston
- Director of Toxicology - San Diego
- Board Advisor - USA
- Country Manager (Generics) - UK
Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag?#CMOncologyNews.
If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me. As a head-hunter specializing in the Oncology industry, I partner with leading drug discovery companies to help them attract and retain top talent globally. Drop me a message and let's catch up.
